Evidence map›Paper›PMID 40901445›Full record

ArticleJournal of advanced pharmaceutical technology & research

2-((3-(chloromethyl) benzoyl) oxy) benzoic acid suppresses NF-κB expression in the kidneys and lungs of LPS-Induced BALB/C mice.

Kuncoro Foe, Philipus Karel, Martha Ervina, Yudy Tjahjono, Hendy Wijaya, Bernadette Dian Novita Dewi, Claritta Angelina Wiyanto Putri, Fransiskus Regis Partana, Michelle Angelina, Sianty Dewi and 4 more

Abstract read
In one paragraph

Article in Journal of advanced pharmaceutical technology & research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kuncoro FoeDepartement of Cellular Pharmacology, Faculty of Pharmacy, Widya Mandala Catholic University, Surabaya, East Java, Indonesia.
Philipus KarelDepartement of Cellular Pharmacology, Faculty of Pharmacy, Widya Mandala Catholic University, Surabaya, East Java, Indonesia.
Martha ErvinaDepartement of Cellular Pharmacology, Faculty of Pharmacy, Widya Mandala Catholic University, Surabaya, East Java, Indonesia.
Yudy TjahjonoDepartement of Cellular Pharmacology, Faculty of Pharmacy, Widya Mandala Catholic University, Surabaya, East Java, Indonesia.
Hendy WijayaDepartement of Cellular Pharmacology, Faculty of Pharmacy, Widya Mandala Catholic University, Surabaya, East Java, Indonesia.
Bernadette Dian Novita DewiDepartement of Pharmacology, Faculty of Medicine, Widya Mandala Catholic University, Surabaya, East Java, Indonesia.
Claritta Angelina Wiyanto PutriDepartement of Cellular Pharmacology, Faculty of Pharmacy, Widya Mandala Catholic University, Surabaya, East Java, Indonesia.
Fransiskus Regis PartanaDepartement of Cellular Pharmacology, Faculty of Pharmacy, Widya Mandala Catholic University, Surabaya, East Java, Indonesia.
Michelle AngelinaDepartement of Cellular Pharmacology, Faculty of Pharmacy, Widya Mandala Catholic University, Surabaya, East Java, Indonesia.
Sianty DewiDepartement of Pharmacology, Faculty of Medicine, Widya Mandala Catholic University, Surabaya, East Java, Indonesia.
Senny Yesery EsarDepartement of Cellular Pharmacology, Faculty of Pharmacy, Widya Mandala Catholic University, Surabaya, East Java, Indonesia.
Wuryanto HadinugrohoDepartement of Cellular Pharmacology, Faculty of Pharmacy, Widya Mandala Catholic University, Surabaya, East Java, Indonesia.
Hevi WihadmadyatamiDepartment of Anatomy, Faculty of Veterinary Medicine, Gadjah Mada University, Karangmalang, Yogyakarta, Indonesia.
CarolineDepartement of Cellular Pharmacology, Faculty of Pharmacy, Widya Mandala Catholic University, Surabaya, East Java, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis, a life-threatening systemic inflammatory condition, is a leading cause of mortality worldwide. Its pathophysiology involves the activation of nuclear factor kappa beta (NF-κB), which promotes the release of proinflammatory cytokines. Acetylsalicylic acid (ASA), a widely used nonsteroidal anti-inflammatory drug, inhibits NF-κB but poses risks of peptic ulcer disease and nephrotoxicity. This study evaluates the efficacy of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid (3-CH

Indexed as

3-CH2Clacetylsalicylic acidimmunohistochemistryinflammationlipopolysaccharideNF-κB

Identifiers

PMID40901445
PMCPMC12401516

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.